Yamamoto H, Hayashi E, Nakamura H, Kimura Y, Ito H, Kambe H
Third Department of Internal Medicine, Osaka University School of Medicine, Japan.
Hepatogastroenterology. 1992 Oct;39(5):377-80.
We treated four cases of acute unresolving non-A, non-B hepatitis, and eleven cases of chronic non-A, non-B hepatitis with recombinant interferon alpha-2a for up to one year. The dose of interferon was initially 3 million units daily, and was gradually decreased to 1 million units three times weekly. The overall response rate was 80 percent (twelve out of fifteen cases) at the end of treatment. Relapse occurred after the cessation of treatment in seven of the eight cases of chronic disease responding to interferon therapy. In contrast, three of the four cases of acute unresolving hepatitis became (sero)negative for antibody to hepatitis C virus, and in three completely normal serum aminotransferase levels persisted for more than one year after therapy. It is urged that early recognition of non-A, non-B hepatitis should be striven for, because interferon therapy may lead to an improved prognosis of the disease, particularly in cases of possible transitional phase from acute to chronic disease.
我们用重组干扰素α-2a治疗了4例急性迁延性非甲非乙型肝炎和11例慢性非甲非乙型肝炎，疗程长达一年。干扰素的初始剂量为每日300万单位，之后逐渐减至每周三次，每次100万单位。治疗结束时，总体有效率为80%（15例中的12例）。在8例对干扰素治疗有反应的慢性疾病患者中，有7例在治疗停止后复发。相比之下，4例急性迁延性肝炎中有3例丙肝病毒抗体转为（血清学）阴性，且有3例在治疗后血清转氨酶水平持续完全正常超过一年。应努力争取早期识别非甲非乙型肝炎，因为干扰素治疗可能改善该病的预后，特别是在可能从急性向慢性疾病转变的阶段。
